The quarter was far ahead of the standing benchmark. Published estimates were roughly $26.9 million for revenue and $0.15 for EPS; Eton delivered $37.6 million of revenue and $0.43 of non-GAAP diluted EPS.
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Revenue | $37.6M (Net Revenue) | $18.9M prior year; ~$26.9M consensus |
| Revenue growth | 99% (Net Revenue) | — |
| GAAP diluted EPS | $0.35 (Net Income/Loss) | $(0.10) prior year |
| Non-GAAP diluted EPS | $0.43 (Net Income/Loss) | $0.03 prior year |
| Adjusted gross margin | 73% (Net Revenue) | 75% prior year |
| Adjusted G&A | $10.2M (R&D / G&A Expenses) | $7.6M prior year |
HEMANGEOL was the key surprise, not just an acquisition accounting boost. The product contributed new revenue after its May relaunch, while roughly 95% of existing patients had transitioned to Eton’s support program by the end of June. That conversion rate reduces the immediate execution risk around the relaunch and gives the company a stronger base for the second half. (HEMANGEOL relaunch section)
The guidance increase materially resets the year. Revenue guidance moved from more than $120 million to more than $145 million, while the minimum adjusted EBITDA margin rose from 30% to 35%. Management says the higher profitability target already absorbs the $3 million ASN-001 licensing expense, added development spending, and a potential $4 million ALKINDI milestone. (Guidance section)
The quality of growth is strong, though margins softened slightly. Adjusted gross margin declined to 73% from 75%, mainly because international INCRELEX sales carry negative gross margin. That is a genuine mix headwind, but it was outweighed by near-doubling revenue, a swing to GAAP profitability, and broad growth across the endocrinology and metabolic portfolio. (Net Revenue; Net Income/Loss)
The net read is a clear beat with more than one quarter of upside. HEMANGEOL’s contribution and the prior $120 million revenue guide were already partly known, so the novelty is primarily the magnitude of the launch performance and the new $145 million outlook. The filing also adds future optionality through ASN-001, KHINDIVI’s potential label expansion, AMGLIDIA, and the September IMPAVIDO launch, but those remain development or launch milestones rather than current revenue contributors. (HEMANGEOL relaunch; Guidance; IMPAVIDO; Development sections)
Read the original 8-K on SEC EDGAR ↗